News

Class of 2015: New drugs projected to earn billions and billions


 

References

Of all drugs to be released in 2015, the melanoma drug Opdivo (nivolumab) is expected to have the brightest future, according to a report from Thomson Reuters.

With sales forecast to reach nearly $5.7 billion by 2019, Opdivo is at the head of a large 2015 “blockbuster” drug class. Opdivo is followed by a pair of drugs for the cardiovascular system: Praluent (alirocumab) for hypercholesterolemia with projected sales of $4.4 billion and LCZ-696 (sacubitril and valsartan) for chronic heart failure with projected 2019 sales of $3.7 billion, Thomson Reuters said.

With estimated sales of $2.8 billion, the breast cancer drug Ibrance (palbociclib) is the second oncologic drug making the blockbuster list, with the first noncancer or non-CV drug – lumacaftor plus ivacaftor for cystic fibrosis – rounding out the Top 5 with projected sales of $2.7 billion by 2019.

Next comes Viekira Pak (ombitasvir, paritaprevir, and ritonavir tablets, copackaged with dasabuvir tablets), a hepatitis C virus drug with estimated 2019 sales of $2.5 billion, followed by the hypercholesterolemia/hyperlipidemia drug evolocumab, with projected sales of $1.9 billion. This $2.5 billion disparity between evolocumab and Praluent may be explained by Praluent’s arrival on the market a month sooner, and also because Praluent had a reduced rate of cardiac death, heart attack, and stroke in a phase III trial, a point likely to be relevant to most patients, according to the report.

Overall, 11 drugs are expected to reach $1 billion in sales by 2019, many more than the three blockbusters predicted from the 2014 stock of drugs. However, the two highest-selling new drugs from 2014, Sovaldi (sofosbuvir) and Harvoni (sofosbuvir plus ledipasvir) – both HCV drugs – are each predicted to reach sales of more than $10 billion by 2017, far exceeding anything from 2015, the report said.

The Thomson Reuters Market Insight Report used data collected from 2013 through early February 2015.

lfranki@frontlinemedcom.com

Recommended Reading

Supreme Court ponders patenting of human genes
Breast Cancer ICYMI
How will sequestration affect American cancer care?
Breast Cancer ICYMI
Supreme Court: Human genes cannot be patented
Breast Cancer ICYMI
Minimizing cancer’s impact on bone with denosumab: current and future perspectives
Breast Cancer ICYMI
Single-drug chemo for breast cancer makes ASCO’s Choosing Wisely list
Breast Cancer ICYMI
Will 100% coverage spur more use of breast cancer chemopreventives?
Breast Cancer ICYMI
Whole-genome sequencing not ready for prime time
Breast Cancer ICYMI
Physician education gaps impact breast density laws
Breast Cancer ICYMI
Apple’s ResearchKit
Breast Cancer ICYMI
Medicare advisers: Cancer prognostic tests not ready for prime time
Breast Cancer ICYMI